Calcium -Sensing Receptor on Neutrophil Promotes Myocardial Apoptosis and Fibrosis After Acute Myocardial Infarction via NLRP3 In flammasome Activation

被引:45
|
作者
Ren, Ziqi [1 ,2 ]
Yang, Kelaier [3 ]
Zhao, Meng [1 ]
Liu, Wenxiu [1 ]
Zhang, Xin [1 ]
Chi, Jinyu [1 ]
Shi, Zhiyu [1 ]
Zhang, Xiaohui [1 ]
Fu, Yu [1 ]
Liu, Yue [1 ]
Yin, Xinhua [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 1, Dept Cardiol, Harbin, Peoples R China
[2] Capital Med Univ, Beijing Tiantan Hosp, Dept Hyperbar Oxygen, Beijing, Peoples R China
[3] Harbin Med Univ, Affiliated Hosp 1, Dept Endocrinol, Harbin, Peoples R China
基金
中国国家自然科学基金;
关键词
ISCHEMIA-REPERFUSION; INFLAMMASOME; POTASSIUM; MAGNESIUM; INJURY;
D O I
10.1016/j.cjca.2019.09.026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The infiltration of neutrophils aggravates inflammatory response in acute myocardial infarction (AMI), and the role of calcium-sensing receptor (CaSR) in neutrophil-associated inflammation is largely unknown. The aim of this study was to evaluate the regulatory effects of CaSR on nucleotide-binding oligomerization domain-like receptor pyrin domain-containing 3 (NLRP3) inflammasome in neutrophils and to explore its role in AMI-related ventricular remodelling. Methods: The expression of CaSR, NLRP3 inflammasome, and interleukin 1β (IL-1β) in peripheral blood and infiltrating neutrophils in patients and rats with AMI was detected by western blotting and immunofluorescence. Cardiomyocyte apoptosis was detected by western blotting and transmission electron microscopy. The degree of fibrosis was evaluated by Masson staining and western blotting. Results: We found upregulation of CaSR, NLRP3 inflammasome, Caspase-1, and IL-1β in peripheral neutrophils from patients with AMI compared with matched healthy controls, peaking on day 1 and decreasing gradually till 7 days. Peripheral and infiltrating neutrophils from rats with AMI showed the same trend. Calindol enhanced NLRP3 inflammasome activation and IL-1β release in neutrophils from healthy volunteers, which was blocked by inhibitors of the PLC-IP3 pathway and ER-Ca2+ release. Calhex-231 decreased NLRP3 inflammasome activation and IL-1β release in neutrophils from patients with AMI. The calindol-stimulated neutrophils from healthy rats promoted cardiomyocyte apoptosis and fibrosis of cardiac fibroblasts from healthy rats, which were inhibited by calhex-231. Conclusion: The results suggest that CaSR activates NLRP3 inflammasome in neutrophils, contributing to ventricular remodelling after AMI. CaSR inhibition may be a potential therapeutic target for heart failure in AMI. © 2019 Canadian Cardiovascular Society
引用
收藏
页码:893 / 905
页数:13
相关论文
共 50 条
  • [21] Glycogen synthase kinase-3β inhibition alleviates activation of the NLRP3 inflammasome in myocardial infarction
    Wang, Shuhui
    Su, Xueling
    Xu, Lina
    Chang, Cheng
    Yao, Yu
    Komal, Sumra
    Cha, Xuexiang
    Zang, Mingxi
    Ouyang, Xinshou
    Zhang, Lirong
    Han, Shengna
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2020, 149 : 82 - 94
  • [22] PRELP promotes myocardial fibrosis and ventricular remodelling after acute myocardial infarction by the wnt/?-catenin signalling pathway
    Zhang, Yu
    Fu, Chunli
    Zhao, Shaohua
    Jiang, Honglei
    Li, Wei
    Liu, Xiangju
    CARDIOVASCULAR JOURNAL OF AFRICA, 2022, 33 (05) : 228 - 233
  • [23] Retinol-Binding Protein 4 Promotes Cardiac Injury After Myocardial Infarction Via Inducing Cardiomyocyte Pyroptosis Through an Interaction With NLRP3
    Zhang, Kang-Zhen
    Shen, Xi-Yu
    Wang, Man
    Wang, Li
    Sun, Hui-Xian
    Li, Xiu-Zhen
    Huang, Jing-Jing
    Li, Xiao-Qing
    Wu, Cheng
    Zhao, Can
    Liu, Jia-Li
    Lu, Xiang
    Gao, Wei
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (22):
  • [24] The receptor for advanced glycation endproducts promotes allergen driven neutrophil dominant airway inflammation via NLRP3 inflammasome activation
    Killian, Katherine N.
    Kosanovich, Jessica L.
    Lipp, Madeline A.
    Empey, Kerry M.
    Oury, Tim D.
    Perkins, Timothy N.
    FASEB JOURNAL, 2022, 36
  • [25] Celastrol relieves myocardial infarction-induced cardiac fibrosis by inhibiting NLRP3 inflammasomes in rats
    Fan, Jiwen
    Ren, Meng
    Chen, Weiwei
    Wang, Haodong
    He, Yuquan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 121
  • [26] Targeting glycogen synthase kinase-3β inhibition alleviates acute myocardial infarction through reduction of NLRP3 inflammasome activation
    Wang, Shuhui
    Xu, Lina
    Chang, Cheng
    Yao, Yu
    Su, Xueling
    Cha, Xuexiang
    Komal, Sumra
    Wang, Peng
    Ouyang, Xinshou
    Zhang, Lirong
    Han, Shengna
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2020, 140 : 38 - 39
  • [27] Hydrogen gas inhalation ameliorates cardiac remodelling and fibrosis by regulating NLRP3 inflammasome in myocardial infarction rats
    Nie, Chaoqun
    Zou, Rentong
    Pan, Shuang
    Rong, A.
    Gao, Yunan
    Yang, Hongxiao
    Bai, Juncai
    Xi, Shuiqing
    Wang, Xue
    Hong, Xiaojian
    Yang, Wei
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021, 25 (18) : 8997 - 9010
  • [28] TXNIP aggravates cardiac fibrosis and dysfunction after myocardial infarction in mice by enhancing the TGFB1/Smad3 pathway and promoting NLRP3 inflammasome activation
    Zhang, Yan
    Wang, Jin
    Wang, Xuejiao
    Li, Aiyun
    Lei, Zhandong
    Li, Dongxue
    Xing, Dehai
    Zhang, Yichao
    Su, Wanzhen
    Jiao, Xiangying
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2023, 55 (12) : 1950 - 1960
  • [29] ALKBH5 promotes cardiac fibroblasts pyroptosis after myocardial infarction through Notch1/NLRP3 pathway
    Cui, Liu-Gen
    Wang, Shu-Hui
    Komal, Sumra
    Yin, Jian-Jian
    Zhai, Miao-Miao
    Zhou, Yue-Jiao
    Yu, Qing-Wen
    Wang, Cong
    Wang, Pei
    Wang, Zhi-Mo
    Zafar, Aliza Muhammad
    Shakeel, Muhammad
    Zhang, Li-Rong
    Han, Sheng-Na
    CELLULAR SIGNALLING, 2025, 127
  • [30] Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes
    Buckley, Leo F.
    Libby, Peter
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2019, 74 (04) : 297 - 305